Cas:214353-20-5 (3aR)-1,2,3,3a,4,5-Hexahydropyrrolo[1,2-a]quinoxaline manufacturer & supplier

Chemical Name:(3aR)-1,2,3,3a,4,5-Hexahydropyrrolo[1,2-a]quinoxaline

CAS.NO:214353-20-5

Synonyms:(3aR)-1,2,3,3a,4,5-Hexahydropyrrolo[1,2-a]quinoxaline

Molecular Formula:C₁₁H₁₄N₂

Molecular Weight:174.24200

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:15.27000

Exact Mass:174.11600

LogP:2.28390

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like (3aR)-1,2,3,3a,4,5-Hexahydropyrrolo[1,2-a]quinoxaline chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(3aR)-1,2,3,3a,4,5-Hexahydropyrrolo[1,2-a]quinoxaline physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(3aR)-1,2,3,3a,4,5-Hexahydropyrrolo[1,2-a]quinoxaline Use and application,(3aR)-1,2,3,3a,4,5-Hexahydropyrrolo[1,2-a]quinoxaline technical grade,usp/ep/jp grade.

Related News: Taiwan previously participated as an observer at the World Health Assembly, the W.H.O.��s governing body. (3aR)-1,2,3,3a,4,5-Hexahydropyrrolo[1,2-a]quinoxaline manufacturer The cell product candidate is being developed under a collaboration with Memorial Sloan Kettering Cancer Center (MSK) led by Michel Sadelain, MD, PhD. (3aR)-1,2,3,3a,4,5-Hexahydropyrrolo[1,2-a]quinoxaline supplier Genzyme Pharmaceuticals develops and manufactures chemically synthesized pharmaceutical materials and technologies for the global pharmaceutical industry and focuses on lipids, peptides, carbohydrates, oligonucleotides, and custom small molecules. (3aR)-1,2,3,3a,4,5-Hexahydropyrrolo[1,2-a]quinoxaline vendor The cell product candidate is being developed under a collaboration with Memorial Sloan Kettering Cancer Center (MSK) led by Michel Sadelain, MD, PhD. (3aR)-1,2,3,3a,4,5-Hexahydropyrrolo[1,2-a]quinoxaline factory What’s more, also at the EHA meeting, BeiGene’s Brukinsa showed it could outperform Imbruvica at triggering tumor responses while causing fewer cases of atrial fibrillation, a potentially dangerous heart side effect, in its own head-to-head phase 3 study in previously treated CLL.